Phase Ia trial of a polynucleotide anti-tumor immunization to human carcinoembryonic antigen in patients with metastatic colorectal cancer. Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.
D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000818:Animals; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002985:Clinical Protocols; D015179:Colorectal Neoplasms / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D010957:Plasmids; D014611:Vaccination
D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D006514:Hepatitis B Surface Antigens